Advertisement
Screener

Sunshine Biopharma Inc. (SBFM) Business Acquisition, Pro Forma Earnings Per Share, Diluted

2.8 / 5 stars · 68/120 Roast Me

Sunshine Biopharma Inc. Business Acquisition, Pro Forma Earnings Per Share, Diluted

Sunshine Biopharma Inc. (SBFM) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$1.74 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-04-04.

Discontinued › Income Statement › Earnings Per Share

us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2023-04-04

  • Sunshine Biopharma Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2022 was -$1.74.
  • Sunshine Biopharma Inc. business acquisition, pro forma earnings per share, diluted for fiscal 2021 was -$4.70.
Period endBusiness Acquisition, Pro Forma Earnings Per Share, Diluted 12 month
2022-12-31-$1.74
10-K · filed 2023-04-04
2021-12-31-$4.70
10-K · filed 2023-04-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aptevo Therapeutics Inc. (APVO)United States$0.003B
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
Genprex, Inc. (GNPX)United States$0.003B-0.02
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Onconetix, Inc. (ONCO)United States$0.004B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B